{"id":568861,"date":"2021-10-13T16:04:01","date_gmt":"2021-10-13T16:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=568861"},"modified":"2021-10-13T16:04:01","modified_gmt":"2021-10-13T16:04:01","slug":"prurigo-nodularis-pipeline-drugs-and-companies-insight-report-2021-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/prurigo-nodularis-pipeline-drugs-and-companies-insight-report-2021-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_568861.html","title":{"rendered":"Prurigo Nodularis Pipeline Drugs and Companies Insight Report, 2021: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1634097651.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Prurigo Nodularis Pipeline Drugs and Companies Insight Report, 2021: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" src=\"https:\/\/www.abnewswire.com\/uploads\/1634097651.png\" alt=\"Prurigo Nodularis Pipeline Drugs and Companies Insight Report, 2021: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cPrurigo Nodularis \u2013 Pipeline Insight, 2021,\u201d report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Prurigo Nodularis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s<strong> <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/prurigo-nodularis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">&ldquo;Prurigo Nodularis Pipeline Insight&rdquo;<\/a><\/strong> report provides comprehensive insights about key companies and pipeline drugs in the Prurigo Nodularis pipeline landscapes.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report comprises <strong>Prurigo Nodularis pipeline<\/strong>drug profiles, including clinical and non-clinical stage products. It also includes the Prurigo Nodularis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Prurigo Nodularis pipeline products.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/756003b93462968384b8b99f8388716d.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Prurigo Nodularis Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Prurigo nodularis is an intensely pruritic, chronic skin condition characterized by localized or generalized hyperkeratotic papules and nodules typically in a symmetrical distribution. Prurigo nodularis is accompanied by long-standing pruritus and is thought to develop as a reaction to repeated scratching in patients with Chronic Prurigo from various etiologies, including dermatological, systemic, infectious, and psychiatric.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key takeaways from the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/prurigo-nodularis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">Prurigo Nodularis Pipeline Report<\/a>:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Menlo Therapeutics, Trevi Therapeutics, Galderma, Dupixent, Amagen, Kiniksa Pharmaceuticals, Maruho, etc., are developing therapies for the treatment of Prurigo Nodularis.<\/p>\n<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Emerging therapies such as Serlopitant, Nalbuphine ER, Nemolizumab, Sanofi\/ Regeneron, Apremilast, KPL-716, M118103, are expected to have a significant impact on the Prurigo Nodularis market in the coming years.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get an overview of pipeline landscape <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/prurigo-nodularis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">@ Prurigo Nodularis Clinical Trials Analysis&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Prurigo Nodularis Pipeline Therapies along with Key Players:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Serlopitant :Menlo Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Nalbuphine ER: Trevi Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Nemolizumab: Galderma&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Sanofi\/ Regeneron:Dupixent&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Apremilast: Amagen<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">KPL-716:Kiniksa Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">M118103:Maruho<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope of Prurigo Nodularis Pipeline Drug Insight&nbsp;&nbsp;&nbsp;&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Coverage: Global&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Major Players: Menlo Therapeutics, Trevi Therapeutics, Galderma, Dupixent, Amagen, Kiniksa Pharmaceuticals, Maruho, and others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pipeline Therapies: Serlopitant, Nalbuphine ER, Nemolizumab, Sanofi\/ Regeneron, Apremilast, KPL-716, M118103, and others.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"22\" \/>\n<col width=\"386\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>1<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prurigo Nodularis Report Introduction<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>2<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prurigo Nodularis Executive Summary<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>3<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prurigo Nodularis Overview<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>4<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prurigo Nodularis-Analytical Perspective In-depth Commercial Assessment<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>5<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prurigo Nodularis Pipeline Therapeutics<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>6<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prurigo Nodularis Late Stage Products (Phase II\/III)<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>7<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prurigo Nodularis Mid Stage Products (Phase II)<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>8<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prurigo Nodularis Early Stage Products (Phase I)<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>9<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prurigo Nodularis Preclinical Stage Products<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>10<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prurigo Nodularis Therapeutics Assessment<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>11<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prurigo Nodularis Inactive Products<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>12<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Company-University Collaborations (Licensing\/Partnering) Analysis<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>13<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prurigo Nodularis Key Companies<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>14<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prurigo Nodularis Key Products<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>15<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prurigo Nodularis Unmet Needs<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>16&nbsp;<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prurigo Nodularis Market Drivers and Barriers<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>17<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prurigo Nodularis Future Perspectives and Conclusion<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>18<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Prurigo Nodularis Analyst Views<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>19<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>Appendix<\/strong><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>20<\/strong><\/p>\n<\/td>\n<td>\n<p dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get a customized pipeline report <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/prurigo-nodularis-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">@ Prurigo Nodularis Drugs Pipeline Report<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=prurigo-nodularis-pipeline-drugs-and-companies-insight-report-2021-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=prurigo-nodularis-pipeline-drugs-and-companies-insight-report-2021-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s, \u201cPrurigo Nodularis \u2013 Pipeline Insight, 2021,\u201d report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Prurigo Nodularis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/prurigo-nodularis-pipeline-drugs-and-companies-insight-report-2021-analysis-of-clinical-trials-therapies-mechanism-of-action-route-of-administration-and-developments_568861.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-568861","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/568861","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=568861"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/568861\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=568861"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=568861"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=568861"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}